Seth Lederman - Feb 23, 2023 Form 4 Insider Report for Tonix Pharmaceuticals Holding Corp. (TNXP)

Role
Chief Executive Officer, Director
Signature
/s/ Seth Lederman
Stock symbol
TNXP
Transactions as of
Feb 23, 2023
Transactions value $
$0
Form type
4
Date filed
2/24/2023, 05:34 PM
Previous filing
Jul 1, 2022
Next filing
Feb 29, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TNXP Stock Option Award $0 +700K $0.00 700K Feb 23, 2023 Common Stock 700K $0.73 Direct F1, F2
transaction TNXP Stock Option Award $0 +700K $0.00 700K Feb 23, 2023 Common Stock 700K $0.91 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 One-third of the option vests on the first anniversary of issuance and 1/36th each month thereafter for 24 months.
F2 The option was granted pursuant to the Issuer's Amended and Restated 2020 Stock Incentive Plan.